AUPH
Aurinia Pharmaceuticals Inc.
1W: +2.1%
1M: -1.5%
3M: -11.9%
YTD: -6.4%
1Y: +68.5%
3Y: +55.9%
5Y: +6.0%
$14.37
+0.16 (+1.13%)
After Hours: $14.46 (+0.09, +0.59%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$22.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.9B
52W Range6.825-16.54
Volume857,134
Avg Volume979,720
Beta1.59
Dividend—
Analyst Ratings
Company Info
CEOPeter S. Greenleaf
Employees130
SectorHealthcare
IndustryBiotechnology
IPO Date2014-09-03
Websiteauriniapharma.com
4464 Markham Street
Edmonton, BC V8Z 7X8
CA
Edmonton, BC V8Z 7X8
CA
12507084272
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Latest News
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
Aurinia Pharmaceuticals appoints Kevin Tang as CEO
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Keenan Greg | F-InKind | 8,069 | $14.32 | 2026-03-06 |
| TANG KEVIN | P-Purchase | 184,208 | $14.22 | 2026-03-03 |
| Miller Joseph M | F-InKind | 37,511 | $14.21 | 2026-03-02 |
| Donley Matthew Maxwe | F-InKind | 40,761 | $14.21 | 2026-03-02 |
| Greenleaf Peter | F-InKind | 100,890 | $14.21 | 2026-03-02 |